Cocaine Use Disorder Clinical Trial
Official title:
Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders
Changes in the communication of glutamate from one brain structure to another are important in the development of therapy for cocaine use disorders. Our preliminary investigations suggest that drugs that affect glutamate exchange may be effective at promoting and maintaining individuals' abstinence from cocaine. The purpose of this randomized, double-blind, controlled trial is to test various glutamate modulators in conjunction with motivational enhancement therapy (MET) and mindfulness based relapse prevention (MBRP) for cocaine use disorders.
Alterations in the transmission between neurons of a neurotransmitter called glutamate are an important target of pharmacotherapy for cocaine use disorders (CUDs). Preliminary investigations suggest that glutamate modulation may be effective at promoting and maintaining abstinence and that it promotes motivation to quit, reduces craving, reduces cocaine self-administration and facilitates abstinence in individuals with a CUD in a series of trials. The study team has recently developed and tested a novel design that integrates a clinical trial involving serial infusions and a behavioral treatment platform. The current trial will evaluate the effect of two sub-anesthetic infusions on abstinence rates in a relatively large sample of treatment-seeking CUD individuals who complete a 12-week double-blind, randomized, controlled trial. It will also evaluate the correlation between clinical response and brain-derived neurotrophic factor (BDNF), a peripheral biomarker relevant to glutamate modulation antidepressant response. This project aims to expand on several years of promising preliminary data to rigorously evaluate the efficacy of this innovative pharmacological intervention integrated into a behavioral treatment platform. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03538548 -
Treatment Outcome in CBT for Cocaine Use
|
N/A | |
| Recruiting |
NCT04994821 -
tDCS to Reduce Craving in Cocaine Addiction- Phase 2 Study
|
Phase 2 | |
| Not yet recruiting |
NCT06050304 -
CRACK-TARGET 1: ÉTUDE DESCRIPTIVE DE LA SENSIBILISATION COMPORTEMENTALE OBSERVÉE et ATTENTES
|
||
| Completed |
NCT02233647 -
Phendimetrazine and Cocaine
|
Early Phase 1 | |
| Completed |
NCT02239913 -
Topiramate-Phentermine Combinations for Cocaine Dependence
|
Phase 1 | |
| Not yet recruiting |
NCT05974202 -
rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder
|
Phase 2 | |
| Recruiting |
NCT04927143 -
Encouraging Abstinence Behavior in a Drug Epidemic
|
Phase 2 | |
| Completed |
NCT03224546 -
Cocaine Use Reduction and Health
|
N/A | |
| Recruiting |
NCT03656653 -
Imagery-based Coping for Cocaine Use Disorder
|
N/A | |
| Completed |
NCT03348384 -
[11C]NOP-1A and Cocaine Use Disorders
|
Early Phase 1 | |
| Recruiting |
NCT05019430 -
Cocaine and Zolmitriptan
|
Early Phase 1 | |
| Recruiting |
NCT05507814 -
Temporal Window and Episodic Future Thinking in CUD
|
N/A | |
| Active, not recruiting |
NCT03799341 -
Neurocognitive Factors in Substance Use Treatment Response: The Ways of Rewarding Abstinence Project
|
N/A | |
| Completed |
NCT02798627 -
Trial Of NS2359 For The Treatment of Cocaine Dependence
|
Phase 2 | |
| Completed |
NCT02785406 -
Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use
|
Phase 2 | |
| Completed |
NCT02444208 -
A Feasibility Trial for Inhibitory-Control Training to Reduce Cocaine Use
|
N/A | |
| Recruiting |
NCT05902819 -
Reconsolidation Blockade of Intrusive Trauma- and Cocaine-related Memories
|
N/A | |
| Recruiting |
NCT05521854 -
Contingency Management for Drug Use: Does Age Matter?
|
N/A | |
| Recruiting |
NCT05833529 -
Innovative Cognitive and Behavioral Psychotherapy for Cocaine Use Disorder
|
N/A | |
| Completed |
NCT05557149 -
Virtual Reality Exposure and Respiratory Relaxation-Based Coping With Cocaine Craving in Cocaine Users
|
N/A |